Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
ACE Report #8861
Ace Report Cover Osteoarthritis

OARSI 2016: IA 20mg & 40mg extended-release triamcinolone acetonide vs placebo for knee OA

Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A

Sustained and profound analgesic benefits in people with osteoarthritis of the knee using FX006, an intra-articular extended-release formulation of triamcinolone acetonide: results from a double-blind, randomized, parallel-group, dose-ranging study

Contributing Authors: PG Conaghan S Cohen J Jordan F Berenbaum J Lufkin C Wilwerth M Clayman MK Doyle N Bodick

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.


306 patients with Kellgren-Lawrence grade II-III knee osteoarthritis were randomized to one of three groups for intra-articular injection: 20mg extended-release triamcinolone acetonide, 40mg extended-release acetonide (ER TCA), or placebo. The purpose of this study was to examine and compare the efficacy of groups based on pain reduction relative to baseline over the first 24 weeks post-injection....

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.